A detailed history of Pathstone Family Office, LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Pathstone Family Office, LLC holds 1,635 shares of UTHR stock, worth $581,634. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,635
Holding current value
$581,634
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$211.82 - $248.24 $346,325 - $405,872
1,635 New
1,635 $369,000
Q4 2022

Oct 23, 2023

BUY
$205.95 - $280.43 $304,600 - $414,755
1,479 New
1,479 $411,000
Q4 2022

Feb 13, 2023

BUY
$205.95 - $280.43 $205 - $280
1 Added 0.07%
1,479 $411,000
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $128,079 - $153,827
630 Added 74.29%
1,478 $309,000
Q2 2022

Aug 15, 2022

BUY
$174.81 - $241.14 $148,238 - $204,486
848 New
848 $200,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.